Back to results
US 12,576,044 B2Granted
Treatment of Alzheimer's disease
OwnerPaul A. Knepperinventor
Life of this patent
Estimating the term…
Abstract
Neurodegenerative diseases are treated by the co-administration to a subject of an effective amount of a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist. A preferred stilbene is resveratrol, a preferred flavonol is quercetin, and a preferred TLR4/MD2 receptor antagonist is curcumin.
Claims7
A method of treating a subject suffering from Alzheimer's Disease which comprises administering to the subject a synergistic amount of resveratrol, quercetin, and curcumin.
Dependencies are inferred from the claim text.